Abstract
The purpose of this study was to compare the response rate, overall and 1-year survival in patients with advanced melanoma treated with a standard therapy, dacarbazine and interferon-alpha (DTIC/IFN), or combination chemotherapy, consisting of dacarbazine, BCNU, cisplatin and tamoxifen (DBCT). Treatment toxicity and time spent in hospital were secondary end points. One hundred and five patients (of whom 100 were eligible) were randomized to receive either DTIC/IFN or DBCT. The trial was designed to detect a 25% absolute difference in response rate or in 1-year survival with 80% power. There was no significant difference in response rate: this was 17.3% with DTIC/IFN and 26.4% with DBCT. Median overall survival was similar at 199 and 202 days respectively. One-year survival rate favoured standard treatment (30.6 vs 22.6%), but did not differ significantly between arms. DBCT was associated with significantly greater haematological toxicity, and a greater need for time spent in hospital (5.75 days/treatment cycle vs 2.29 with dacarbazine and interferon). DBCT combination therapy cannot be recommended as standard treatment for advanced melanoma. Dacarbazine remains the standard chemotherapy for this condition. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Atkins M (1997) The treatment of metastatic melanoma with chemotherapy and biologics. Curr Opin Oncol 9: 205–213
Balch CM, Reintgen DS and Kirkwood JM (1997) Cutaneous melanoma. In: Cancer: Principles and Practice of Oncology, 5th edn., De Vita VT Jr, Hellman S and Rosenberg SA (eds), pp. 1947–1994, Lippincott-Raven: Philadelphia
Bajetta E, Di-Leo A, Zampino MG, Sertoli MR, Comella G, Barduagni M, Giannotti B, Queriolo P, Tribbia G and Bernengo MG (1994) Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alpha-2a in the treatment of advanced melanoma. J Clin Oncol 12: 806–812
Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AH and Kirkwood JM (1999) Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17: 2745–2752
del Prete SA, Maurer LH, O'Donnell J, Forcier RJ and LeMarbre P (1984) Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma. Cancer Treat Rep 68: 1403–1405
Falkson CI, Falkson G and Falkson HC (1991) Improved results with the addition of interferon alpha-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 9: 1403–1410
Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB and Blum RH (1998) Phase III trial of dacarbazine versus dacarbazine with interferon α-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon α-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 16: 1743–1751
Johnston SR, Costenla DO, Moore J, Atkinson H, Ahern RP, Dadian G, Riches PG and Gore ME (1998) Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer 77: 1280–1286
Keilholz U, Conradt C, Legha S, Khayat D, Scheibenbogen C, Thatcher N, Goey SH, Gore M, Dorval T, Hancock B, Punt CJA, Dummer R, Avril MF, Brocker EB, Benhammouda A, Eggermont AA and Pritsch M (1998) Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 16: 2921–2929
Lakhani S, Selby P, Bliss JM, Perren TJ, Gore ME and McElwain TJ (1990) Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit. Br J Cancer 61: 330–334
Lee SM, Betticher DC and Thatcher N (1995) Melanoma: chemotherapy. Br Med Bull 51: 609–630
Legha SS, Ring S, Bedikian A, Plager C, Eton O, Buzaid AC and Papadopoulos N (1996) Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-α. Ann Oncol 7: 827–836
Luikart SD, Kennealy GT and Kirkwood JM (1984) Randomized phase III trial of vinblastine, bleomycin and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol 2: 164–168
McClay EF, Mastrangelo MJ, Berd D and Bellet RE (1992) Effective combination of chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer 50: 553–556
Margolin KA, Liu PY, Flaherty LE, Sosman JA, Walker MJ, Smith JWIII, Fletcher WS, Weiss GR, Unger JM and Sondak VK (1998) Phase II study of carmustine, dacarbazine, cisplatin and tamoxifen in advanced melanoma: a Southwest Oncology Group study. J Clin Oncol 16: 664–669
Mulder NH, van der Graaf WTA, Willemse PHB, Schraffordt Koops H, de Vries EGE and Sleijfer DT (1994) Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma. Br J Cancer 70: 681–683
Nathanson L, Kaufman SD and Carey RW (1981) Vinblastine infusion, bleomycin and cis-dichlorodiammine-platinum chemotherapy in metastatic melanoma. Cancer 48: 1290–1294
National Cancer Institute of Canada Melanoma Group (1984) Vinblastine, bleomycin and cis-platinum for the treatment of metastatic malignant melanoma. J Clin Oncol 2: 131–134
Richards J, Mehta N, Ramming K and Skosey P (1992) Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 10: 1338–1342
Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Mmarincola FM, Topalian SL, Seipp CA, Einhorn JH, White DE and Steinberg SM (1999) Prospective randomized trial of the treatment of metastatic melanoma patients using chemotherapy with cisplatin, dacarbazine and tamoxifen alone or in combination with interleukin-2 and interferon alpha-2b. J Clin Oncol 17: 968–973
Rusthoven JJ, Quirt IC, Iscoe McCulloch PB, James KW, Lohmann RC, Jensen J, Burdette-Radoux S, Bodurtha AJ, Silver HKB, Verma S, Armitage GR, Zee B and Bennett K (1996) Randomized, double-blind, placebo-controlled trial comparing response rates of carmustine, dacarbazine and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol 14: 2083–2090
Schultz MZ, Buzaid AC and Poo WJ (1997) A phase II study of interferon-alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma. Melanoma Res 7: 147–151
Thompson JA, Gold PJ and Fefer A (1997) Outpatient chemoimmunotherapy for the treatment of metastatic melanoma. Semin Oncol 24: S44–S48
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Middleton, M., Lorigan, P., Owen, J. et al. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 82, 1158–1162 (2000). https://doi.org/10.1054/bjoc.1999.1056
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.1999.1056
Keywords
This article is cited by
-
Temozolomide in combination with fotemustine in patients with metastatic melanoma
Cancer Chemotherapy and Pharmacology (2008)
-
Combination chemotherapy with or without s.c. IL-2 and IFN-α: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)
British Journal of Cancer (2002)
-
Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line
Cancer Gene Therapy (2001)
